scholarly journals Benign Histiocyte-Rich Pseudotumor Developing Postchemotherapy and Mimicking Residual Disease

2020 ◽  
Vol 2020 ◽  
pp. 1-5
Author(s):  
Amrit P. Singh ◽  
Glenn P. Murray ◽  
Soumya Pandey
Keyword(s):  
Residual Disease ◽  
B Cell Lymphoma ◽  
Excisional Biopsy ◽  
Ct Imaging ◽  
Response To Treatment ◽  
Large B Cell Lymphoma ◽  
Positron Emission ◽  
Pet Ct ◽  
History Of ◽  
Relapsed Disease

Histiocyte-rich pseudotumors (HRPT) developing postchemoradiation therapy are a florid response to treatment and reparative change. Although these are benign processes, clinically and radiologically, these may mimic recurrent/relapsed disease. We describe a case of an adult male with history of diffuse large B-cell lymphoma (DLBCL), status postchemoradiation therapy, who developed HRPT at the site of original involvement, mimicking relapse of disease on positron emission tomography/computed tomography (PET/CT) imaging. This is one of the few reported cases of posttreatment HRPT. This entity is important to point out the limitations of PET/CT imaging in patients with lymphomas and metastatic disease and stresses the importance of an excisional biopsy for determining relapse and the need for further treatment.

scholarly journals Primary Mediastinal B-Cell Lymphoma: Novel Precision Therapies and Future Directions

2021 ◽  
Vol 11 ◽  
Author(s):  
Huan Chen ◽  
Tao Pan ◽  
Yizi He ◽  
Ruolan Zeng ◽  
Yajun Li ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
New Drugs ◽  
Response To Treatment ◽  
Prognostic Features ◽  
Quantitative Pet ◽  
Large B Cell Lymphoma ◽  
Pet Ct ◽  
Large B Cell

Primary mediastinal large B-cell lymphoma (PMBCL) is a distinct clinicopathologic disease from other types of diffuse large B-cell lymphoma (DLBCL) with unique prognostic features and limited availability of clinical data. The current standard treatment for newly diagnosed PMBCL has long been dependent on a dose-intensive, dose-adjusted multi-agent chemotherapy regimen of rituximab plus etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-R-EPOCH). Recent randomized trials have provided evidence that R-CHOP followed by consolidation radiotherapy (RT) is a valuable alternative option to first-line treatment. For recurrent/refractory PMBCL (rrPMBCL), new drugs such as pembrolizumab and CAR-T cell therapy have proven to be effective in a few studies. Positron emission tomography-computed tomography (PET-CT) is the preferred imaging modality of choice for the initial phase of lymphoma treatment and to assess response to treatment. In the future, baseline quantitative PET-CT can be used to predict prognosis in PMBCL. This review focuses on the pathology of PMBCL, underlying molecular basis, treatment options, radiotherapy, targeted therapies, and the potential role of PET-CT to guide treatment choices in this disease.

scholarly journals Post-mortem diagnosis of intravascular large B-cell lymphoma

2020 ◽  
Vol 48 (6) ◽  
pp. 030006052092426
Author(s):  
Aniello Maiese ◽  
Raffaele La Russa ◽  
Alessandra De Matteis ◽  
Paola Frati ◽  
Vittorio Fineschi
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Lymphoid Cells ◽  
Resonance Imaging ◽  
Large B Cell Lymphoma ◽  
Positron Emission ◽  
Atypical Cells ◽  
History Of ◽  
Large B Cell

Intravascular large B-cell lymphoma (IVLBCL) is a rare (<1%), typically aggressive extranodal variant of mature non-Hodgkin B-cell lymphoma. IVLBCL is characterized by malignant lymphoid cells lodged within blood vessels, particularly capillary channels. Herein, we present a case of a 50-year-old man with a history of myeloradiculitis (∼1 year) and paraparesis requiring hospitalization. During the course of his hospital stay, computed tomography (CT), magnetic resonance imaging, CT-positron emission tomography, and biopsy failed to establish a diagnosis. The patient died 2 months later from bilateral pneumonia. Postmortem examination was undertaken to determine the cause of death. Histologic sections of the patient’s brain, heart, lung, and liver showed aggregates of highly atypical cells bearing enlarged, pleomorphic, and hyperchromatic nuclei. Strong intravascular positivity for CD45 and CD20 markers indicated the cells were of B-cell origin, supporting a diagnosis of IVLBCL.

18F-FDG PET/CT Imaging in Detection of Intravascular Large B-Cell Lymphoma

2016 ◽  
Vol 5 (1) ◽  
pp. 10-11
Author(s):  
Chuantao Zuo ◽  
◽  
Fangyang Jiao ◽  
Jingjie Ge ◽  
Zhongwen Zhou ◽  
...  
Keyword(s):  
B Cell ◽  
Fdg Pet ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Ct Imaging ◽  
Large B Cell Lymphoma ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
Large B Cell

Utility of the PET–CT in the evaluation of early response to treatment in the diffuse large B-cell lymphoma. Preliminary results

2012 ◽  
Vol 31 (3) ◽  
pp. 135-141 ◽  
Author(s):  
M. Cortés Romera ◽  
C. Gámez Cenzano ◽  
A.P. Caresia Aróztegui ◽  
J. Martín-Comín ◽  
E. González-Barca ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Early Response ◽  
Response To Treatment ◽  
Preliminary Results ◽  
Large B Cell Lymphoma ◽  
Pet Ct ◽  
Large B Cell

scholarly journals Recurrent diffuse large B-cell lymphomamimicking primary breast cancer

Mastology ◽  
2021 ◽  
Vol 31 ◽  
Author(s):  
David Caetano Bastos ◽  
Eduardo Nóbrega Pereira Lima ◽  
Almir Galvão Vieira Bitencourt ◽  
Paula Nicole Vieira Pinto Barbosa
Keyword(s):  
Breast Cancer ◽  
B Cell ◽  
Primary Breast Cancer ◽  
B Cell Lymphoma ◽  
Histopathological Analysis ◽  
Large B Cell Lymphoma ◽  
Positron Emission ◽  
Pet Ct ◽  
Magnetic Resonance Imaging Mri ◽  
Large B Cell

Breast lymphoma can represent 0.8%–2.2% of extranodal lymphomas and 0.1%–0.5% of primary breast neoplasms. Imaging findings are not specific, and its distinction from primary invasive breast carcinoma should be based on clinical data and histopathological analysis. We present the case of a 62-year-old woman who showed an unusual pattern of recurrent diffuse large B-cell lymphoma (DLBCL) mimicking primary breast cancer on imaging studies, including mammography, ultrasound, magnetic resonance imaging (MRI), and positron emission tomography-computed tomography (PET-CT).

scholarly journals Imaging in head and neck cancer: United Kingdom National Multidisciplinary Guidelines

2016 ◽  
Vol 130 (S2) ◽  
pp. S28-S31 ◽  
Author(s):  
H Lewis-Jones ◽  
S Colley ◽  
D Gibson
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Residual Disease ◽  
Ct Imaging ◽  
Cross Sectional ◽  
Positron Emission ◽  
Pet Ct ◽  
Cross Sectional Imaging ◽  
The Uk

AbstractThis guideline is endorsed by the specialty associations involved in the care of head and neck cancer patients in the UK. This paper summarises the current imaging modalities in use for head and neck cancer evaluation. It highlights their role in the management with recommendations on modality choice for each cancer subsite.Recommendations• Offer appropriate radiological imaging, based on tumour extent, site and local expertise, to stage tumours and plan treatment for patients diagnosed with head and neck cancer. (G)• Consider positron emission tomography combined with computed tomography (PET–CT) imaging if conventional cross-sectional imaging identifies no primary site. (R)• Offer PET–CT imaging 12 weeks after non-surgical treatment to detect residual disease. (R)

scholarly journals A Case of Double Expresser Diffuse Large B Cell Lymphoma Treated with R-CODOX-M/R-IVAC

2019 ◽  
Vol 12 (2) ◽  
pp. 595-602 ◽  
Author(s):  
Thomas Bemis ◽  
Jonathan Ioanitescu ◽  
Lynn Mackovick ◽  
Azzam Hammad ◽  
Jascha Rubin
Keyword(s):  
B Cell ◽  
Chromosomal Abnormalities ◽  
Metabolic Response ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Response To Treatment ◽  
High Dose ◽  
Large B Cell Lymphoma ◽  
Pet Ct ◽  
Large B Cell

Diffuse Large B Cell Lymphoma (DLBCL) is a heterogeneous disease with a variety of chromosomal abnormalities contributing to differences in management. While it is known that Double Hit Lymphomas (DHL) warrant more aggressive chemotherapy regimens, debate remains on how to treat Double Expresser Lymphomas (DEL). We present a case of a DEL treated with an aggressive regimen of 2 alternating cycles of R-CODOX-M (rituximab, cyclophosphamide, doxorubicin, vincristine and methotrexate) and R-IVAC (rituximab, ifosfamide, etoposide and high dose cytarabine). The regimen resulted in a significant response to treatment with marked reduction in tumor size and avidity, and an acceptable side effect profile. There was, however, residual metabolic activity on repeat PET CT scan. After consolidation with 36 Grey radiotherapy, a PET CT demonstrated a complete metabolic response. Debate remains regarding treatment approaches in DEL. Our case supports the categorization of DEL alongside DHL as resistant lymphomas requiring a more aggressive regimen than standard therapy.

scholarly journals 18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Management of Aggressive Non-Hodgkin's B-Cell Lymphoma

2012 ◽  
Vol 2012 ◽  
pp. 1-9 ◽  
Author(s):  
M. J. Shelly ◽  
S. McDermott ◽  
O. J. O'Connor ◽  
M. A. Blake
Keyword(s):  
B Cell ◽  
Fdg Pet ◽  
Cell Lymphoma ◽  
Imaging Modality ◽  
B Cell Lymphoma ◽  
Cost Effective ◽  
Response To Treatment ◽  
Positron Emission ◽  
Pet Ct ◽  
Fdg Pet Ct

18-Fluorodeoxyglucose (FDG-PET/CT) is an established imaging modality that has been proven to be of benefit in the management of aggressive B-cell non-Hodgkin's lymphoma, such as diffuse large B-cell lymphoma and advanced stage follicular lymphoma. The combination of anatomic and functional imaging afforded by FDG-PET/CT has led to superior sensitivity and specificity in the primary staging, restaging, and assessment of response to treatment of hematological malignancies when compared to FDG-PET and CT alone. The use of FDG-PET/CT for posttreatment surveillance imaging remains controversial, and further study is needed to ascertain whether this modality is cost effective and appropriate for use in this setting.

Sign in / Sign up

Export Citation Format

Share Document